SAN DIEGO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Morgan Stanley Global Healthcare Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a fireside chat at 12:55 pm Eastern Time on Wednesday, September 14, 2022, at the Sheraton Hotel in New York, New York. Drs. Lim and Chacko will also participate in one-on-one investor meetings.

Read this article:
Erasca to Present at the Morgan Stanley Global Healthcare Conference

MAINZ, Germany, September 9, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today presented positive follow-up data from its ongoing first-in-human Phase 1/2 trial evaluating the safety and efficacy of the Company’s novel CAR-T cell therapy candidate, BNT211, in patients with relapsed or refractory advanced solid tumors. The results demonstrated encouraging signs of anti-tumor activity and the safety profile remained manageable for the two tested dose levels. The data were presented in the Investigational Immunotherapy Proffered Paper Session at the European Society for Medical Oncology (ESMO) Congress 2022 by Prof. Andreas Mackensen, M.D., University Hospital Erlangen, Germany.

Read more:
BioNTech Presents Encouraging Phase 1/2 Follow-up Data for CAR-T Candidate BNT211 in Hard-To-Treat Solid Tumors at ESMO

Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress

Read more here:
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress

See original here:
Orion Corporation: Acquisition of Own Shares 09.09.2022

OSLO, Norway, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that its Chief Executive Officer, Michael Engsig, and Chief Business Officer & Co-founder, Agnete Fredriksen, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Tuesday, September 13, 2022 at 11:00 a.m. ET / 5:00 p.m. CET and are available for 1:1 investor meetings.

Read the rest here:
Nykode Therapeutics to present at H.C. Wainwright 24th Annual Global Investment Conference

New York, NY, and Tel Aviv, ISRAEL, Sept. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today released the Nasdaq MarketSite interview between Moneta Advisory Group’s Managing Partner Marc LoPresti and CEO Gerald Commissiong, discussing the impact of Long COVID on the economy and how SARS-CoV-2 viral persistence is damaging population-level immunity leading to the rise of viral outbreaks such as MonkeyPox. A link to the interview can be found at: https://youtu.be/55pv1zKCDgI.

Read more:
Todos Medical CEO Discusses Long COVID Economic Impact with Moneta Advisory Managing Partner Marc LoPresti

SEATTLE, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentations at two investor conferences in September. The presentations will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.

Go here to read the rest:
Sana Biotechnology to Present at September 2022 Investor Conferences

SAN CARLOS, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming investor conferences:

See the original post:
Atreca to Present at Upcoming Investor Conferences

GAITHERSBURG, Md., Sept. 09, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Kristi Jones, Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12 at 11:00 am ET.

See more here:
NexImmune to Present at the H.C. Wainwright 24th Annual Global Investment Conference

PORTLAND, Ore., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) (the “Company” or “Chalice Brands”), a premier consumer-driven cannabis company specializing in retail, production, processing, wholesale, and distribution, announced today that it has terminated its previously announced definitive agreements and services agreements (the “Agreements”) dated April 20, 2022, with Miracle Greens, Inc (“Miracle Greens”) and Totem Farms, LLC (“Totem Farms”).

More here:
Chalice Brands Ltd. Announces Termination of Totem Farms & Miracle Greens Transactions

Basel, September 10, 2022 — Novartis announced the results from two pivotal, Phase III studies (SUNSHINE and SUNRISE), in which Cosentyx® (secukinumab) demonstrated rapid and sustained relief from the common clinical signs and symptoms of moderate-to-severe hidradenitis suppurativa (HS) with a favorable safety profile5,6. The data were presented as a late-breaking abstract at the 31st European Academy of Dermatology and Venereology (EADV) Congress1.

Continue reading here:
Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials

- ANV419 is well-tolerated at high doses and demonstrates notable safety with strong pharmacodynamic effects and excellent IL-2Rbg selectivity –

Read the rest here:
Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022

Newly published poster on the single-arm 27-patient safety and dosimetry lead-in provides key updates including:

See the original post:
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022

Go here to read the rest:
Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology...

Top-line findings were presented today at the annual European Society for Medical Oncology (ESMO) Congress

Go here to read the rest:
Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival Versus Sorafenib in...

- Best-in-class profile demonstrated with repeat dosing across dose levels -

Visit link:
Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4...

PHILADELPHIA, Sept. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today presented updated clinical and translational data through 6 months of follow-up in cohorts A1 through A4 as well as 28-day safety data and DSG3-CAART persistence data through day 29 for cohorts A1 through A5 from the DesCAARTes™ trial at the 31st European Academy of Dermatology and Venereology (EADV) Congress, which is being held in Milan, Italy from September 7-10, 2022.

More here:
Cabaletta Bio Presents New Interim Data from the DesCAARTes™ Phase 1 Trial at the 31st EADV Congress

-Sotigalimab in combination with neoadjuvant chemoradiation induced higher pathologic complete response rates, an important predictor of survival, in patients with both adenocarcinoma and squamous cell carcinoma- -Sotigalimab in combination with neoadjuvant chemoradiation induced higher pathologic complete response rates, an important predictor of survival, in patients with both adenocarcinoma and squamous cell carcinoma-

View original post here:
Apexigen Presents New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients...

ImCheck Therapeutics today presented promising updated safety and patient response data from the completed dose escalation combination cohort of its ongoing EVICTION clinical trial during an oral session at the European Society for Medical Oncology (ESMO) Congress currently being held in Paris, France. EVICTION is an open-label Phase I/IIa study evaluating ImCheck’s lead antibody ICT01 as a monotherapy in both solid tumor and hematological cancers, and in combination with pembrolizumab in solid tumors.

Read more from the original source:
Presents Positive Safety and Efficacy Data from the Completed Phase 1 Dose Escalation Cohort of ICT01 plus Pembrolizumab in the EVICTION Trial at...

– Nirogacestat Treatment Resulted in Rapid, Sustained and Statistically Significant Improvements in Primary and All Key Secondary Efficacy Endpoints –

Read the original post:
SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the...